NMDP BioTherapies Appoints New President to Lead Next Phase in Life-Saving Therapy Development

Tom Hochuli will lead the organization as it renews its commitment to advancing cell and gene therapy MINNEAPOLIS , Jan. 30, 2024 — NMDP BioTherapies℠, formerly Be The Match BioTherapies, announced that Tom Hochuli will serve as president, leading the organization into its promising future phase. The appointment comes at a significant time for NMDP, which underwent…

International regulations for allogeneic cell source material

When you procure cellular starting material or distribute a cell or gene therapy product across international borders, you must consider the country or regional regulatory requirements at play and where they diverge. Allogeneic cell therapy sponsors face common challenges when treating a global patient population with therapies using healthy adult donor starting material.